Course Description
Part 2 shifts from recognition to optimization and treatment, opening with a rigorous framework for hormone assessment—when serum, saliva, or urine each tells the truth, how to read “normal labs but feels terrible,” and what estrogen-metabolite and clearance patterns imply for therapy and cancer risk. From there it surveys a therapeutic toolkit: repurposed medications, breast-health considerations, and systemic proteolytic enzymes weighed against NSAIDs for pain and inflammation. The session then explores metabolic levers—sugar metabolism, fasting and fasting-mimicking diets and their effects on immunosenescence, and the rapidly evolving GLP class, with practical attention to mechanism, monitoring, motility, and muscle preservation. It closes with high-utility neuro-metabolic and adjunctive pearls: differentiating fatigue from boredom and depression through dopamine and arousal, plus targeted approaches to restless leg syndrome, melatonin, shingles, and exercise as cancer-risk modification.
Learning Objectives
- Select the appropriate hormone-testing modality (serum, salivary, or urinary) for a given clinical question and interpret discordant results, including estrogen-metabolite and cortisol-clearance patterns.
- Formulate individualized hormone-related management plans and articulate the considerations linking hormone therapy to cancer risk and protection.
- Compare the pharmacology and monitoring requirements of GLP-1, GLP-1/GIP, and triple-agonist medications, including effects on motility, electrolytes, lean mass, and body composition.
- Integrate metabolic and longevity-oriented interventions—fasting and fasting-mimicking diets, systemic enzymes versus NSAIDs, and exercise—into adjunctive cancer and chronic-disease strategies.
- Distinguish fatigue from boredom and depression using dopamine and mental-arousal frameworks, and apply targeted protocols for restless leg syndrome, melatonin use, and shingles.
Sponsor: Biotics Research Corporation